Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 486

1.

Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer.

Xiao Y, Zhang S, Hou G, Zhang X, Hao X, Zhang J.

Tumour Biol. 2014 Mar;35(3):2035-45. doi: 10.1007/s13277-013-1270-5. Epub 2013 Oct 5.

PMID:
24096546
2.

Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes.

Hou G, Zhang S, Zhang X, Wang P, Hao X, Zhang J.

Breast Cancer Res Treat. 2013 Feb;137(3):807-16. doi: 10.1007/s10549-012-2404-y. Epub 2013 Jan 6.

PMID:
23292119
3.

Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.

He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC.

Ann Oncol. 2012 Jul;23(7):1771-80. doi: 10.1093/annonc/mdr534. Epub 2011 Nov 22.

4.

Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer.

Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM.

Cancer. 2012 Mar 1;118(5):1202-11. doi: 10.1002/cncr.26439. Epub 2011 Jul 28.

5.

Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

J Surg Res. 2007 Nov;143(1):109-18.

PMID:
17950079
6.

Type 2 diabetes mellitus and prognosis in early stage breast cancer women.

Kaplan MA, Pekkolay Z, Kucukoner M, Inal A, Urakci Z, Ertugrul H, Akdogan R, Firat U, Yildiz I, Isikdogan A.

Med Oncol. 2012 Sep;29(3):1576-80. doi: 10.1007/s12032-011-0109-4. Epub 2011 Nov 15.

PMID:
22083554
7.

[Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].

Zhang HM, Zhang BN, Xuan LX, Zhao P.

Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):447-51. Chinese.

PMID:
19950556
8.

[Clinical features and prognosis analysis of different breast cancer molecular subtypes].

Yang Q, Chen J, Li HJ, Yu M, Tian CX, Lü Q.

Zhonghua Zhong Liu Za Zhi. 2011 Jan;33(1):42-6. Chinese.

PMID:
21575463
9.

Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.

Cortesi L, De Matteis E, Cirilli C, Marcheselli L, Proietto M, Federico M.

Tumori. 2012 Nov;98(6):743-50. doi: 10.1700/1217.13498.

PMID:
23389361
10.

[Clinical characteristics and prognosis of different subtypes of breast cancer].

Yuan ZY, Wang SS, Zhu MQ, Zheng L, Luo WB, Zhou ZM, Guan ZZ.

Zhonghua Zhong Liu Za Zhi. 2008 Jun;30(6):456-61. Chinese.

PMID:
19024523
11.

Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes.

Kim HJ, Kwon H, Lee JW, Kim HJ, Lee SB, Park HS, Sohn G, Lee Y, Koh BS, Yu JH, Son BH, Ahn SH.

Breast Cancer Res. 2015 May 3;17:64. doi: 10.1186/s13058-015-0574-3.

12.

Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.

Milde-Langosch K, Karn T, Müller V, Witzel I, Rody A, Schmidt M, Wirtz RM.

Breast Cancer Res Treat. 2013 Jan;137(1):57-67. doi: 10.1007/s10549-012-2296-x. Epub 2012 Nov 8.

PMID:
23135572
13.

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO.

J Natl Cancer Inst. 2009 May 20;101(10):736-50. doi: 10.1093/jnci/djp082. Epub 2009 May 12.

14.

Pathological features and prognosis of different molecular subtypes of breast cancer.

Wang GS, Zhu H, Bi SJ.

Mol Med Rep. 2012 Oct;6(4):779-82. doi: 10.3892/mmr.2012.981. Epub 2012 Jul 9.

PMID:
22797840
15.

Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information.

Feeley LP, Mulligan AM, Pinnaduwage D, Bull SB, Andrulis IL.

Mod Pathol. 2014 Apr;27(4):554-61. doi: 10.1038/modpathol.2013.153. Epub 2013 Sep 20.

16.

Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China.

Xue C, Wang X, Peng R, Shi Y, Qin T, Liu D, Teng X, Wang S, Zhang L, Yuan Z.

Cancer Sci. 2012 Sep;103(9):1679-87. doi: 10.1111/j.1349-7006.2012.02339.x. Epub 2012 Jul 4.

17.

Pre-diagnostic smoking behaviour and poorer prognosis in a German breast cancer patient cohort - Differential effects by tumour subtype, NAT2 status, BMI and alcohol intake.

Seibold P, Vrieling A, Heinz J, Obi N, Sinn HP, Flesch-Janys D, Chang-Claude J.

Cancer Epidemiol. 2014 Aug;38(4):419-26. doi: 10.1016/j.canep.2014.05.006. Epub 2014 Jun 17.

PMID:
24950597
18.

Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

Ann Surg Oncol. 2007 Oct;14(10):2994-3003. Epub 2007 Jul 24.

PMID:
17647064
19.

A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.

Wang Y, Yin Q, Yu Q, Zhang J, Liu Z, Wang S, Lv S, Niu Y.

Breast Cancer Res Treat. 2011 Nov;130(2):489-98. doi: 10.1007/s10549-011-1709-6. Epub 2011 Aug 12.

PMID:
21837481
20.

Clinical features and survival analysis of different subtypes of patients with breast cancer brain metastases.

Bai B, Yuan ZY, Liu DG, Teng XY, Wang SS.

Chin J Cancer. 2010 Apr;29(4):413-9.

Items per page

Supplemental Content

Write to the Help Desk